

## RESULTS OF EXTRAORDINARY GENERAL MEETING

Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”) advises an Extraordinary General Meeting of the Company was held today, Monday 12 February 2024, commencing at 12pm AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), details of the resolution put to shareholders and proxies received in respect of the resolution are set out in the attached proxy summary.

The resolution put to the Meeting was not carried on a Poll, with approximately 72% of shareholders who voted, voting against the resolution. As a result, Mr Otto Buttula remains a director of the Company.

The Board thanks shareholders for their ongoing support, and post this Meeting, looks forward to refocussing on core business activities.

- ENDS -

### Authorisation & Additional Information

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com) or on +61 3 8256 2880:**

<b>Mr. Otto Buttula</b> Executive Chairman	<b>Mr. James Barrie</b> Joint Company Secretary
---	--

### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

### Directors

Otto Buttula  
Sue MacLeman  
Trevor Lockett  
Louis Panaccio

Executive Chairman  
Independent Deputy Chair  
Non-Executive Director  
Non-Executive Director

[www.rhythmbio.com](http://www.rhythmbio.com)

**T** +61 3 8256 2880  
**E** [info@rhythmbio.com](mailto:info@rhythmbio.com)

Disclosure of Proxy Votes  
Rhythm Biosciences Limited  
Extraordinary General Meeting  
12 February 2024



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to the resolutions put to members at the meeting, which were **decided on a Poll**.

		Proxy Votes						Poll			Result
	Resolution	For	Against	Open	Exclusions	Abstain	Total	For	Against	Abstain	Carried / Not Carried
Resolution 1	REMOVAL OF CURRENT DIRECTOR - OTTO	56,679,620	70,480,318	717,113	-	502,250	127,877,051	57,180,982	73,268,550	502,254	Not Carried
	BUTTULA	44.32%	55.12%	0.56%				43.83%	56.17%		